Search Results80 results found
CSL’s Seqirus and the University of Liverpool Pandemic Institute launch major strategic collaboration to advance influenza protection and pandemic preparedness
Seqirus – a global leader in influenza prevention and a business of CSL Limited - has entered into a multi-year influenza research partnership with the University of Liverpool Pandemic Institute.
Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.
Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response
Renewal reaffirms longstanding, public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA)
Seqirus is one of the largest influenza vaccine companies in the world, with state-of-the-art manufacturing facilities on three continents. Learn more.
Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives
Seqirus Completes $156 Million Expansion to Holly Springs Manufacturing Facility, Optimizing Global Manufacturing Capabilities for Seasonal and Pandemic Influenza Vaccines
The new pre-filled syringe line has received FDA approval and will support influenza vaccine production for the 2022/23 Northern Hemisphere season and beyond.
Seqirus, a Business of CSL Limited, Announces New Facility Supporting Research & Development of Leading-Edge Influenza Vaccine Technology
New facility in Waltham, Massachusetts, will support CSL’s growing R&D portfolio, including the self-amplifying mRNA technology platform.
Seqirus strengthens U.K. influenza vaccine response as high-speed fill and finish facility begins rolling 30 million doses in Liverpool
First doses of Seqirus’s enhanced influenza vaccine, destined for the U.K., come off a new high-speed fill-and-finish line in Liverpool.